News & updates

LUMC talent Edouard Fu receives NWO Rubicon grant to conduct research at Harvard Medical School

Created on:

October 6, 2021

Edouard Fu, PhD student at the Department of Clinical Epidemiology at the LUMC, uses big data to study the effectiveness and safety of kidney, diabetes and heart failure treatments. With a Rubicon grant from NWO, Edouard will conduct further research at Harvard Medical School over the next two years.

In the first round of Rubicon 2021, a total of 24 newly graduated scientists were selected to conduct research abroad at prestigious institutions such as Oxford and Harvard.

Wonder drugs for diabetics?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new group of medications used for treating patients with type 2 diabetes, kidney disease, or heart failure. The potential impact of this novel medication class is enormous: type 2 diabetes currently affects more than 400 million people worldwide, whereas heart failure is the leading cause of hospitalizations in the Western world.

Considered a breakthrough in the treatment of diabetes and heart failure, Edouard Fu – however – highlights that initial clinical trials on the effectiveness and safety of SGLT2 inhibitors do not portray the whole picture quite yet. “These trials included very selective patient populations and their study size and duration is often not sufficient to investigate rare – but potentially serious safety outcomes. By applying cutting-edge statistical methods to big data of more than 200 million patients, we will be able to investigate the effectiveness and safety of these drugs in patients with diabetes and heart failure in a real-life setting.”

Read the full article here.

More news & updates

Dr. Jeremia J. Pyuza: From Scientific Collaboration to Community Impact in Tanzania

June 16, 2024

In the third edition of our “Faces Behind LUMC Global” interview series Dr. Jeremia J. Pyuza, a medical doctor and laboratory scientist, tells us the inspiring story of his journey from Tanzania to the Netherlands. Through his passion for research, he is committed to making an impact within rural and urban communities of his home country Tanzania.

Jogchum Beltman: From Tropical Doctor in Malawi to Gynecologist-Oncologist in Leiden

July 13, 2024

In the fourth edition in our “Faces Behind LUMC Global” series, Dr. Jogchum Beltman, a gynecologist-oncologist at LUMC brings us back to the early days of his career as a tropical doctor in Malawi and his current work as a medical specialist. A story about his experiences and the challenges he faced in this exciting field.

Indonesian Fathimah Sigit obtains her PhD for international research on obesity and metabolic syndrome

May 2, 2022

Global epidemics come in many forms and attract different kinds of attention depending on the severity of the diseases. But as Fathimah’s research demonstrates, there’s a risk that comes with giving too little attention to epidemics that don’t have immediate life altering/threatening effects. It’s for this exact reason that obesity is often overlooked in terms of severity. In the short term, obesity isn’t life threatening perse, but over time, the complications of obesity become progressively more dangerous and ultimately life threatening. With around 40 percent of the global population being overweight and 13 percent suffering from obesity, Fathimah’s recent PhD research on the topic might prove invaluable in the future.